MEBO Group and JDT Asset Launch Xiamen Meijing Consulting with Bay Area Council Partnership

On September 23, MEBO Group President Yang Zhibin, together with Vice Presidents Liu Gang and Shang Qingxin and Investment Director Liu Jindian, visited Xiamen for a strategic signing ceremony with JDT Asset Management (Hong Kong) Limited, officially launching Xiamen Meijing Consulting Co., Ltd. At the same event, a representative of the Bay Area Council presented a cooperation confirmation letter, recognizing Xiamen Meijing as a key partner in overseas services for the biopharmaceutical sector. Representatives from the Xiamen Free Trade Commission, Bay Area Council, and Xiamen International Trade Group also attended the ceremony.

With more than 30 years of expertise in medical and healthcare innovation, MEBO Group has advanced from pioneering skin regeneration therapies to building international markets under the principle of “open cooperation to create a stronger industrial ecosystem.” The establishment of Xiamen Meijing, alongside its deep collaboration with the Bay Area Council, reflects this commitment in practice.

Xiamen Meijing will focus on three areas:

Providing compliance consulting for local biotech companies expanding abroad, leveraging MEBO’s global network and regulatory experience with FDA registration and CE certification;

Building an integrated service system combining consulting, sales channel development, and overseas capital introduction to streamline international expansion;

Facilitating international exchanges through the Bay Area Council to connect Xiamen enterprises with the California market and advanced overseas technologies.

MEBO has pledged strong support for Xiamen Meijing’s growth, including deploying an experienced management team, opening access to global resources, and working closely with JDT Asset and the Bay Area Council. Together, the partners aim to make Xiamen Meijing a benchmark platform for internationalization in the biopharmaceutical industry, injecting new momentum into Xiamen’s industrial upgrading and supporting China’s broader “going global” ambitions.

About MEBO

Founded in 1987 by Professor Rongxiang Xu, a distinguished Chinese life scientist, MEBO Group is a multinational headquartered in both China and the USA. It integrates research, development, and sales across the pharmaceuticals, medical devices, health foods, and cosmetics sectors.

At its core, MEBO focuses on regenerative life sciences, innovating with over 100 patents and more than ten joint research bases to enhance and enable the body's own regenerative abilities.

As a leader in regenerative life science, MEBO's extensive research facilities and products impact over 100 countries globally, pioneering new frontiers in the regenerative life world.